Official Title
Exploratory Clinical Study to Assess the Efficacy of NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia
Brief Summary

This is phase II study to assess the efficacy of NestaCell® (mesenchymal stem cell) to treat severe COVID-19 pneumonia.

Detailed Description

The number of infections of COVID-19 worldwide has killed thousands and is continually rising. The novel coronavirus attacks the human body by attaching to the angiotensin-converting enzyme-2 (ACE2), a protective enzyme against lung damage. In addition, the cellular serine protease TMPRSS2 for HCoV-19 Spike protein priming is also essential for the host cell entry and spread. Coronaviruses can be deadly, in large part because they cause "cytokine storms." These storms result from imbalances between pro-inflammatory and anti-inflammatory proteins called cytokines, which can cause extreme inflammation and respiratory complications. Respiratory distress kills hundreds of thousands of people each year worldwide, and hundreds of clinical trials are testing drugs to treat it.

MSCs have been widely used in cell-based therapy, from basic research to clinical trials Safety and effectiveness have been clearly documented in many clinical trials, especially in the immune-mediated inflammatory diseases.

NestaCell® is a mesenchymal stem cell therapy produced by Cellavita and proved to be safe in previous clinical trials.

The aim of this study is assess the efficacy of NestCell® as an add-on therapy to standard treatment to treat patients with severe COVID-19 pneumonia. .

Patients included will be randomized to receive 2x10^7 cells (20 million cells) on days 1, 3, 5 and 7.

Not yet recruiting
COVID-19 Pneumonia

Biological: NestaCell®
A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
NestaCell®
Other Name: Mesenchymal Stem Cell

Biological: Placebo
Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
Placebo

Eligibility Criteria

Inclusion Criteria:

1. Male or female, aged ≥ 18 years 2. Present a confirmed or pending diagnosis of COVID-19,
but with tomographic and clinical signs strongly suggestive of SARS-CoV-2 infection
(COVID-19), with pulmonary impairment greater than or equal to 50% and: i. Oxygen
saturation

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
Brazil
Contacts

Florentino de Araujo Cardoso Filho
+55 19 991232882
florentino.cardoso@hospitalcare.com.br

Luciana Ferrara
+55 19 981428814
luciana.ferrara@azidusbrasil.com.br

Azidus Brasil
Cellavita Pesquisa Científica Ltda
Hospital Vera Cruz
NCT Number
MeSH Terms
Pneumonia